Vetnox LLC.

PAPiSOL treatment platforms adoption rates 1%, 3%, 6% and 10% oral and 5%, 10%, 15% 20% injectable revenue years 1-4, est. $4.9M, $14.1M, $28.4M $46.9M.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Tucson, Arizona, US
  • Currency USD
  • Founded 2005
  • Employees 3
  • Website anoxacorp.com

Company Summary

VetNOx LLC develops and commercializes additional nitric oxide based technologies for animal health industry. EIPHiSOL treatment For Exercise Induced Pulmonary Hemorrhage in performance horses. Licensing agreements for North America, Australia, New Zealand, Saudi Arabia, Singapore and China. This team has now created VetNOx focused maturing related technologies that address major animal health issues and represent large potential markets.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free